Since BAP1 mutated tumors were significantly associated with worse overall survival than tumors without mutated BAP16, it was essential to investigate the specialized therapeutic agents for the BAP1 mutant ccRCC. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.